GLP-1 Peptide Atlas, by Delfa

CompletedPhase 3Results posted

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus

Lead sponsor

GlaxoSmithKline

Assets

Albiglutide / Liraglutide

Listed sites

173

Recruiting sites

—

Enrollment

841

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7-10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01128894

Org study ID114179

Timeline

Milestones

Study first posted2010-05-24estimated

Results first posted2014-05-20estimated

Last update posted2017-02-23actual

Study start2010-05 (month precision)

Primary completion2011-09actual (month precision)

Study completion2011-09actual (month precision)

Assets

Investigational agents

Albiglutide Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of type 2 diabetes mellitus and experiencing inadequate glycemic control on their current regimen of metformin, TZD, SU, or any combination of these oral antidiabetic medications

•BMI >/=20kg/m2 and </=45 kg/m2

•Fasting C-peptide >/=0.8 ng/mL (>/=0.26 nmol/L)

•HbA1c between 7.0% and 10.0%, inclusive

•Female subjects of childbearing potential must be practicing adequate contraception.

Exclusion criteria

•History of cancer

•History of treated diabetic gastroparesis

•Current biliary disease or history of pancreatitis

•History of significant GI surgery

•Recent clinically significant cardiovascular and/or cerebrovascular disease

•Hypertension

•History of human immunodeficiency virus infection

•History of or current liver disease or acute symptomatic infection with hepatitis B or hepatitis C

•History of alcohol or substance abuse

•Female subject is pregnant, lactating, or <6 weeks postpartum

•Known allergy to any GLP 1 analogue, liraglutide, other study medications' excipients, excipients of albiglutide, or Baker's yeast

•History of type 1 diabetes mellitus

•Contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., liraglutide)

•Receipt of any investigational drug or liraglutide within the 30 days or 5 half lives, whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies

•History or family history of thyroid disease

Endpoints (14)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

2 endpoints

Secondary/registry result

Mean Change From Baseline in Body Weight at Week 32

Time frame:Baseline and Week 32

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), Kilograms	95% CI
Albiglutide 50 mg	-0.62	—
Liraglutide 1.8 mg	-2.21	—

Secondary/protocol endpoint

Mean Change From Baseline in Body Weight at Week 32

Time frame:Baseline and Week 32

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

12 endpoints

Primary/registry result

Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32

Time frame:Baseline and Week 32

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), Percentage of HbA1c in the blood	95% CI
Albiglutide 50 mg	-0.78	—
Liraglutide 1.8 mg	-0.99	—

Mean Difference (Final Values)0.2195% CI0.08 – 0.34p0.0846ANCOVA

Primary/protocol endpoint

Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32

Time frame:Baseline and Week 32

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/registry result

Mean Change From Baseline in HbA1c at Weeks 4, 6, 12, 18 and 26

Time frame:Baseline, Weeks 4, 6, 12, 18 and 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percentage of HbA1c in the blood	95% CI
Albiglutide 50 mgWeek 4, n=387, 392	-0.52	—
Week 6, n=398, 401	-0.66	—
Week 12, n=398, 402	-0.88	—
Week 18, n=398, 402	-0.87	—
Week 26, n=398, 402	-0.79	—
Liraglutide 1.8 mgWeek 4, n=387, 392	-0.73	—
Week 6, n=398, 401	-0.94	—
Week 12, n=398, 402	-1.18	—
Week 18, n=398, 402	-1.13	—
Week 26, n=398, 402	-1.00	—

Secondary/registry result

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 32

Time frame:Baseline and Week 32

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), Millimoles per liter (mmol/L)	95% CI
Albiglutide 50 mg	-1.22	—
Liraglutide 1.8 mg	-1.68	—

Secondary/registry result

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 1, 2, 3, 4, 6, 12, 18 and 26

Time frame:Baseline, Weeks 1, 2, 3, 4, 6, 12, 18 and 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), Millimoles per liter (mmol/L)	95% CI
Albiglutide 50 mgWeek 1, n=386, 381	-0.98	—
Week 2, n= 399, 398	-1.33	—
Week 3, n= 400, 402	-1.61	—
Week 4, n= 400, 402	-1.52	—
Week 6, n= 400, 402	-1.25	—
Week 12, n= 400, 402	-1.73	—
Week 18, n= 400, 402	-1.44	—
Week 26, n= 400, 402	-1.14	—
Liraglutide 1.8 mgWeek 1, n=386, 381	-1.62	—
Week 2, n= 399, 398	-2.25	—
Week 3, n= 400, 402	-2.43	—
Week 4, n= 400, 402	-2.45	—
Week 6, n= 400, 402	-2.11	—
Week 12, n= 400, 402	-2.10	—
Week 18, n= 400, 402	-1.74	—
Week 26, n= 400, 402	-1.64	—

Secondary/registry result

Number of Participants Who Achieved HbA1c Response Level of <6.5% and <7.0% at Week 32

Time frame:Week 32

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), Participants	95% CI
Albiglutide 50 mgHbA1c <6.5%	78	—
HbA1c <7.0%	168	—
Liraglutide 1.8 mgHbA1c <6.5%	113	—
HbA1c <7.0%	208	—

Secondary/registry result

Time to Hyperglycemia Rescue at Week 32

Time frame:Week 32

time to event, event

Posted result

Group	Value (median), Weeks	95% CI
Albiglutide 50 mg	NA	NA – NA
Liraglutide 1.8 mg	NA	NA – NA

Secondary/protocol endpoint

Mean Change From Baseline in HbA1c at Weeks 4, 6, 12, 18 and 26

Time frame:Baseline, Weeks 4, 6, 12, 18 and 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 32

Time frame:Baseline and Week 32

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 1, 2, 3, 4, 6, 12, 18 and 26

Time frame:Baseline, Weeks 1, 2, 3, 4, 6, 12, 18 and 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Number of Participants Who Achieved HbA1c Response Level of <6.5% and <7.0% at Week 32

Time frame:Week 32

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Time to Hyperglycemia Rescue at Week 32

Time frame:Week 32

time to event, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
The lancet. Diabetes & endocrinology2014 Apr (month)PMID24703047doi:10.1016/S2213-8587(13)70214-6via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.